Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialResearch in context

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialResearch in context

Summary: Background: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP in immunocompromised individuals with mild COVID-19. Methods: This randomised, controlled, open-label trial assessed CCP in immun...

Full description

Saved in:
Bibliographic Details
Main Authors: Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, Fabian Halleck, Antoine Durrbach, Lynn Peters, Anna-Teresa Tremmel, Alina Seidel, Marita Führer, Friederike Bachmann, Jens Schrezenmeier, Jochen Greiner, Sixten Körper, Henrike Hofmann, Carolin Ludwig, Christiane Vieweg, Bernd Jahrsdörfer, Klemens Budde, Michael Schmidt, Jan Münch, Nizar Joher, Etienne Daguindau, Beate Grüner, Gaëlle Brunotte, Charline Vauchy, Erhard Seifried, Daniel Bradshaw, Lise J. Estcourt, David J. Roberts, Eric Toussirot, Bart Rijnders, Pierre Tiberghien, Hubert Schrezenmeier
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:EBioMedicine
Subjects:
Convalescent plasma
COVID-19
Randomised trial
Neutralising antibody
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S235239642500057X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S235239642500057X

Similar Items